Literature DB >> 30424891

Pump, pipes, and filter: do SGLT2 inhibitors cover it all?

Subodh Verma1, Peter Jüni2, C David Mazer2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30424891     DOI： 10.1016/S0140-6736(18)32824-1

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  19 in total

Review 1.  Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.

Authors:  Javed Butler; Milton Packer; Stephen J Greene; Mona Fiuzat; Stefan D Anker; Kevin J Anstrom; Peter E Carson; Lauren B Cooper; Gregg C Fonarow; Adrian F Hernandez; James L Januzzi; Mariell Jessup; Rita R Kalyani; Sanjay Kaul; Mikhail Kosiborod; JoAnn Lindenfeld; Darren K McGuire; Marc S Sabatine; Scott D Solomon; John R Teerlink; Muthiah Vaduganathan; Clyde W Yancy; Norman Stockbridge; Christopher M O'Connor
Journal:  Circulation       Date:  2019-12-16       Impact factor: 29.690

Review 2.  Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?

Authors:  Rosalie A Scholtes; Michaël J B van Baar; Yuliya Lytvyn; Petter Bjornstad; Max Nieuwdorp; David Z I Cherney; Daniël H van Raalte
Journal:  Diabetes Obes Metab       Date:  2019-04       Impact factor: 6.577

3.  Cardiovascular and renal protection with sodium-glucose cotransporter type 2 inhibitors: new paradigm in type 2 diabetes management…and potentially beyond.

Authors:  André J Scheen
Journal:  Ann Transl Med       Date:  2019-07

Review 4.  Impact of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging-What Do We Know So Far? (A Narrative Review).

Authors:  Cristina Andreea Adam; Razvan Anghel; Dragos Traian Marius Marcu; Ovidiu Mitu; Mihai Roca; Florin Mitu
Journal:  Life (Basel)       Date:  2022-05-27

Review 5.  Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review.

Authors:  Gary D Lopaschuk; Subodh Verma
Journal:  JACC Basic Transl Sci       Date:  2020-06-22

6.  Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide.

Authors:  Bryce C Simes; Gordon G MacGregor
Journal:  Diabetes Metab Syndr Obes       Date:  2019-10-14       Impact factor: 3.168

Review 7.  Predictors of heart failure development in type 2 diabetes: a practical approach.

Authors:  Subodh Verma; Abhinav Sharma; Naresh Kanumilli; Javed Butler
Journal:  Curr Opin Cardiol       Date:  2019-09       Impact factor: 2.161

Review 8.  Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases.

Authors:  Alaaeldin Bashier; Azza Bin Hussain; Elamin Abdelgadir; Fatheya Alawadi; Hani Sabbour; Robert Chilton
Journal:  Diabetol Metab Syndr       Date:  2019-09-26       Impact factor: 3.320

9.  Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.

Authors:  Ona Kinduryte Schorling; Douglas Clark; Isabella Zwiener; Stefan Kaspers; Jisoo Lee; Hristo Iliev
Journal:  Adv Ther       Date:  2020-05-05       Impact factor: 3.845

10.  SGLT2 inhibition and COVID-19: The road not taken.

Authors:  Liza Das; Pinaki Dutta
Journal:  Eur J Clin Invest       Date:  2020-09-22       Impact factor: 5.722
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.